Plain-English translation of NCT07087860 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach for people with advanced bladder cancer whose disease has stopped responding to previous treatment. The study combines therapeutic plasma exchange (a procedure that filters out harmful substances from your blood) with two medications: and . Researchers believe that cleaning the blood this way might help these medications work better the second time around.
Many patients with advanced bladder cancer stop responding to these medications after an initial period of benefit. This trial is exploring whether removing certain substances from the blood might reset the body's ability to respond to the medication again, offering new hope to patients who have exhausted other options.
You likely qualify if…
You likely don't qualify if…
If you join Group A, you would receive blood filtering on days 1–3 of each treatment cycle, followed by infusions of the two medications. If you join Group B, you would receive standard next-line treatment chosen by your doctor. Either way, you will have regular imaging scans, blood tests, and urine tests throughout the trial, and you'll answer questionnaires about your quality of life and any side effects. Treatment cycles last 3 weeks, and you would continue until your disease progresses or side effects become unmanageable.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States